Advanced in Migraine with Brainstem Aura

Dr. Joel R. Saper

Neurology
3120 Professional Dr, 
Ann Arbor, MI 
Accepting New Patients
Advanced in Migraine with Brainstem Aura
3120 Professional Dr, 
Ann Arbor, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Saper is a Neurologist in Ann Arbor, Michigan. Dr. Saper is rated as an Advanced provider by MediFind in the treatment of Migraine with Brainstem Aura. His top areas of expertise are Migraine, Cluster Headache, Migraine with Brainstem Aura, and New Daily Persistent Headache (NDPH). Dr. Saper is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

3120 Professional Dr, Ann Arbor, MI 48104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drugs: Erenumab, Oral Prophylactic
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drug: Sumatriptan Nasal Powder
Study Phase: Phase 3
Observational Study of Pediatric Migraine: The Pediatric Migraine Registry
Observational Study of Pediatric Migraine: The Pediatric Migraine Registry
Enrollment Status: Completed
Publish Date: April 13, 2021
A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II)
A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II)
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Enrollment Status: Completed
Publish Date: July 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Enrollment Status: Terminated
Publish Date: June 19, 2019
Intervention Type: Device
Study Phase: Not Applicable
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
Enrollment Status: Unknown
Publish Date: June 26, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 11 Less Clinical Trials

22 Total Publications

Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial.
Journal: Cephalalgia : an international journal of headache
Published: January 10, 2022
Similar Doctors
Distinguished in Migraine with Brainstem Aura
Dr. Omar I. Ahmad
Neurology
Distinguished in Migraine with Brainstem Aura
Dr. Omar I. Ahmad
Neurology

Michigan Neuroscience Clinic PLLC

730 N Macomb St, Suite 300, 
Monroe, MI 
 (27.7 miles away)
734-374-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Omar Ahmad is a Neurologist in Monroe, Michigan. Dr. Ahmad is rated as a Distinguished provider by MediFind in the treatment of Migraine with Brainstem Aura. His top areas of expertise are Migraine with Brainstem Aura, Seizures, Generalized Tonic-Clonic Seizure, and Migraine. Dr. Ahmad is currently accepting new patients.

Distinguished in Migraine with Brainstem Aura
Dr. Lauren A. Aymen
Neurology
Distinguished in Migraine with Brainstem Aura
Dr. Lauren A. Aymen
Neurology

Glendale Neurological Associates PC

28595 Orchard Lake Rd, Suite 200, 
Farmington Hills, MI 
 (24.6 miles away)
248-553-0010
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lauren Aymen is a Neurologist in Farmington Hills, Michigan. Dr. Aymen is rated as an Advanced provider by MediFind in the treatment of Migraine with Brainstem Aura. Her top areas of expertise are Migraine, Migraine with Brainstem Aura, Neuralgia, and Trigeminal Neuralgia. Dr. Aymen is currently accepting new patients.

Distinguished in Migraine with Brainstem Aura
Dr. Charles E. Schultz
Neurology
Distinguished in Migraine with Brainstem Aura
Dr. Charles E. Schultz
Neurology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (2.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Schultz is a Neurologist in Ann Arbor, Michigan. Dr. Schultz is rated as an Advanced provider by MediFind in the treatment of Migraine with Brainstem Aura. His top areas of expertise are Migraine, Migraine with Brainstem Aura, Trigeminal Neuralgia, and Familial Hemiplegic Migraine. Dr. Schultz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saper's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile